Literature DB >> 9021182

Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.

G V Doern1, A B Brueggemann, G Pierce, H P Holley, A Rauch.   

Abstract

A total of 1,537 clinical isolates of Haemophilus influenzae were recovered in 30 U.S. medical center laboratories between 1 November 1994 and 30 April 1995 and were characterized in a central laboratory with respect to serotype and beta-lactamase production and the in vitro activities of 15 oral antimicrobial agents. Overall, 36.4% of the isolates were found to produce beta-lactamase. The rank order of activity of six cephalosporins on the basis of MICs was cefixime > cefpodoxime > cefuroxime > loracarbef > or = cefaclor > cefprozil. On the basis of current National Committee for Clinical Laboratory Standards (NCCLS) breakpoints ages of isolates found to be resistant or intermediate to these agents were as follows: 0.1, 0.3, 6.4, 16.3, 18.3, and 29.8, respectively (National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. M7-A4, 1995). Azithromycin was, on a weight basis, the most potent of the macrolides tested in this study, followed by erythromycin and then clarithromycin. Azithromycin was typically fourfold more active than erythromycin, which was, in turn, slightly more active than clarithromycin. However, when compared on the basis of the frequency of resistance determined by using current NCCLS breakpoints, there was essentially no difference between azithromycin and clarithromycin, i.e., 0.5 and 1.9%, respectively (P = 0.086). Interpretive breakpoints for erythromycin MIC tests versus H. influenzae have not been developed. Resistance to other non- beta-lactam agents was variable, as follows: trimethoprim-sulfamethoxazole, 9.0%; chloramphenicol, 0.2%; tetracycline, 1.3%; and rifampin, 0.3%. Two conspicuous findings in this study were the identification of 39 strains H. influenzae that were beta-lactamase negative but ampicillin intermediate or resistant (BLNAR) and, even more surprisingly, 17 beta-lactamase-positive isolates that were resistant to amoxicillin-clavulanate (BLPACR). Strains of H. influenzae in the first group have heretofore been very uncommon; organisms in the second group have not previously been described in the literature. The percentages of all study isolates comprised of BLNAR and BLPACR organisms were 2.5 and 1.1, respectively. Overall resistance to ampicillin was thus 38.9%, and that to amoxicillin-clavulanate was 4.5%.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021182      PMCID: PMC163704     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Chromogenic cephalosporin spot test to detect beta-lactamase in clinically significant bacteria.

Authors:  K Montgomery; L Raymundo; W L Drew
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

2.  Ampicillin-resistant Haemophilus influenzae type B infection.

Authors:  M O Tomeh; S E Starr; J E McGowan; P M Terry; A J Nahmias
Journal:  JAMA       Date:  1974-07-15       Impact factor: 56.272

3.  Haemophilus influenzae type B resistant to ampicillin. A report of two cases.

Authors:  W Khan; S Ross; W Rodriguez; G Controni; A K Saz
Journal:  JAMA       Date:  1974-07-15       Impact factor: 56.272

4.  Isolation of an ampicillin-resistant, non-beta-lactamase-producing strain of Haemophilus influenzae.

Authors:  S M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

5.  Ampicillin treatment failure of apparently beta-lactamase-negative Haemophilus influenzae type b meningitis due to novel beta-lactamase.

Authors:  L G Rubin; A A Medeiros; R H Yolken; E R Moxon
Journal:  Lancet       Date:  1981-11-07       Impact factor: 79.321

6.  Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group.

Authors:  S B Black; H R Shinefield
Journal:  Pediatr Infect Dis J       Date:  1992-08       Impact factor: 2.129

7.  A survey of beta-lactamase-producing Haemophilus influenzae. An evaluation of 5750 isolates.

Authors:  S F Rittenhouse; L A Miller; R L Kaplan; G H Mosely; J A Poupard
Journal:  Diagn Microbiol Infect Dis       Date:  1995-04       Impact factor: 2.803

8.  Broth microdilution testing of Haemophilus influenzae with haemophilus test medium versus lysed horse blood broth. Canadian Haemophilus Study Group.

Authors:  S R Scriver; D E Low; A E Simor; B Toye; A McGeer; R Jaeger
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

9.  In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

Authors:  A L Barry; M A Pfaller; P C Fuchs; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Mechanisms of ampicillin resistance in Haemophilus influenzae from respiratory tract.

Authors:  S M Bell; D Plowman
Journal:  Lancet       Date:  1980-02-09       Impact factor: 79.321

View more
  54 in total

1.  Identification of beta-lactamase-negative, ampicillin-resistant strains of Haemophilus influenzae with four methods and eight media.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria.

Authors:  S K Spangler; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

3.  Characterization of non-type B Haemophilus influenzae strains isolated from patients with invasive disease. The HI Study Group.

Authors:  M Cerquetti; M L Ciofi degli Atti; G Renna; A E Tozzi; M L Garlaschi; P Mastrantonio
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

4.  Antimicrobial surveillance of Haemophilus influenzae in the United States during 2000-2001 leads to detection of clonal dissemination of a beta-lactamase-negative and ampicillin-resistant strain.

Authors:  James A Karlowsky; Ian A Critchley; Renée S Blosser-Middleton; Elena A Karginova; Mark E Jones; Clyde Thornsberry; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 5.  Management of acute otitis media in the 1990s: the decade of resistant pneumococcus.

Authors:  S L Block
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

6.  Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae.

Authors:  K Ubukata; Y Shibasaki; K Yamamoto; N Chiba; K Hasegawa; Y Takeuchi; K Sunakawa; M Inoue; M Konno
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

7.  Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin.

Authors:  Frank S Kaczmarek; Thomas D Gootz; Fadia Dib-Hajj; Wenchi Shang; Shawn Hallowell; Melissa Cronan
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Clinical and Bacteriologic Analysis of Nontypeable Haemophilus influenzae Strains Isolated from Children with Invasive Diseases in Japan from 2008 to 2015.

Authors:  Sachiko Naito; Noriko Takeuchi; Misako Ohkusu; Azusa Takahashi-Nakaguchi; Hiroki Takahashi; Naoko Imuta; Junichiro Nishi; Keigo Shibayama; Mayumi Matsuoka; Yuko Sasaki; Naruhiko Ishiwada
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

Review 9.  Azithromycin. A review of its use in paediatric infectious diseases.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

10.  Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999.

Authors:  F Marco; J García-de-Lomas; C García-Rey; E Bouza; L Aguilar; C Fernández-Mazarrasa
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.